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ABSTRACT
Objectives To assess outcomes of patients admitted to
hospital with COVID-19 and to determine the predictors of
mortality.
Setting This study was conducted in six facilities, which
included both government and privately run secondary and
tertiary level facilities in the central and coastal regions of
Kenya.
Participants We enrolled 787 reverse transcriptase-PCR-
confirmed SARS-CoV2-infected persons. Patients whose
records could not be accessed were excluded.
Primary and secondary outcome measures The
primary outcome was COVID-19-related death. We used
Cox proportional hazards regressions to determine factors
related to in-hospital mortality.
Results Data from patients with 787 COVID-19 were
available. The median age was 43 years (IQR 30–53),
with 505 (64%) being men. At admission, 455 (58%)
were symptomatic with an additional 63 (9%) developing
clinical symptoms during hospitalisation. The most
common symptoms were cough (337, 43%), loss of taste
or smell (279, 35%) and fever (126, 16%). Comorbidities
were reported in 340 (43%), with cardiovascular disease,
diabetes and HIV documented in 130 (17%), 116 (15%),
53 (7%), respectively. 90 (11%) were admitted to the
Intensive Care Unit (ICU) for a mean of 11 days, 52 (7%)
were ventilated with a mean of 10 days, 107 (14%) died.
The risk of death increased with age (HR 1.57 (95% CI
1.13 to 2.19)) for persons >60 years compared with
those <60 years old; having comorbidities (HR 2.34
(1.68 to 3.25)) and among men (HR 1.76 (1.27 to 2.44))
compared with women. Elevated white cell count and
aspartate aminotransferase were associated with higher
risk of death.
Conclusions The risk of death from COVID-19 is high
among older patients, those with comorbidities and among
men. Clinical parameters including patient clinical signs,
haematology and liver function tests were associated with risk
of death and may guide stratification of high-risk patients.

INTRODUCTION
Ten months since the first case of COVID-19
was reported, more than 45 million cases and

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ The main strengths of this study are that it was mul-

ticentre and included asymptomatic and mild cases,
which provides a more comprehensive analysis of
the presentation of COVID-19 and reduces bias.
⇒ Asymptomatic participants were admitted during
the initial phase of the outbreak as part of the outbreak containment measures and this gave opportunity to document progression of disease.
⇒ Limitations of this study include the absence of laboratory parameters for some of the study patients,
pulse oximetry was not routinely recorded during
the initial period of the outbreak, and we did not
have access to other laboratory markers that have
been shown to predict mortality including D-dimers
and IL-6.

1.2 million people have died from the disease
globally. Africa has recorded 1.8 million cases
and 42 000 deaths with South Africa reporting
the most cases on the continent.1 Kenya
reported its first case on 13 March 2020 and
has recorded more than 97 000 cases and
1690 COVID-19 deaths within 10 months with
established community transmission in all the
47 counties as documented by the Ministry of
Health Emergency Operations Centre.
The epidemiological and clinical characteristics of COVID-19 patients are not fully
known. Initial data from China reported a
median age of 47 in patients with COVID-19,
majority of patients were men with only 5%
requiringIntensive care unit care and a 1.4%
mortality.2 On the other hand, limited data
from Africa have reported higher mortality
for patients younger than 20 years compared
with 20–39 year olds,3 which differs significantly from what is reported elsewhere and
underscores the need to understand the
disease dynamics in multiple settings.
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of home-based care guidelines on 12 June 2020. Patients
with COVID-19 of all ages were recruited into the study.
Confirmation of SARS-CoV-2 infection was through real-
time PCR testing of nasal and oral-pharyngeal swabs at
government-designated COVID-19 testing centres.
Patient and public involvement
The study design did not include patient and public
involvement, research questions were informed by the
Kenya national COVID-19 subcommittee on case management and front-line healthcare workers. Results from this
study will be shared with the national COVID-19 task force
and healthcare workers involved in COVID-19 management to inform on stratification and care of patients with
COVID-19.

METHODS
Study design
This multicentre cohort study recruited patients admitted
into six hospitals with laboratory-confirmed diagnosis of
SARS-CoV2 between 14 March 2020 and 17 September
2020. The six hospitals (three public hospitals and three
private hospitals) had provided dedicated facilities with
isolation beds for patients with COVID-19. Two of the
public hospitals (Kenyatta National Referral Hospital
and Mbagathi Hospital) are located in Nairobi while one
public hospital (Coast General Teaching and Referral
Hospital) is in Mombasa County at the Coast. The three
private hospitals (Nairobi Hospital, Aga Khan University
Hospital and Avenue Hospital) are located in Nairobi.
Following the report of the first SARS-CoV-2 case in
Kenya on 13 March 2020, the government policy required
isolation of all infected persons, including those that were
asymptomatic, in health facilities, prior to the adoption

Procedures
We developed a detailed questionnaire that was used
to systematically extract information from the medical
records of patients with COVID-19 admitted into these
study hospitals. Briefly, the questionnaires captured
patient information at admission into the hospital, during
the hospitalisation until discharge or death. Medical
records of the SARS-CoV2-positive patients admitted in
the study hospitals were reviewed by a team of trained
physicians. They extracted data including patient demographic data, medical history, underlying comorbidities,
clinical symptoms, laboratory findings, management
and treatment measures and outcome data. Presenting
symptoms at admission and during the hospital stay were
obtained.
All patients had blood samples drawn for blood count,
liver and renal function tests within 24 hours of admission. Patients who had moderate to severe illness got a
chest radiograph, CRP and D-dimers in facilities where
these investigations were available. Other investigations
were ordered as informed by the clinical scenario. Patients
with low oxygen saturation were given supplemental
oxygen via nasal prongs or masks as appropriate. Patients
requiring further respiratory support were admitted to
the ICU for either non-invasive or invasive ventilation.
At the beginning of the outbreak in Kenya, patients
were given supportive care that included paracetamol for
management of fever and antihistamines for any nasal
congestion, many patients at the time also received various
repurposed drugs, including azithromycin and hydroxychloroquine, in keeping with the little evidence available
at the time. As more data became available, dexamethasone became standard of care for severely ill patients
on oxygen or requiring mechanical ventilation, and the
use of hydroxychloroquine and azithromycin was largely
abandoned. Other supportive care given to patients at the
time included saline gargles and throat lozenges. Patients
with severe illness also received prophylactic anticoagulation with either low-molecular weight or unfractionated
heparin depending on availability at the various sites.
Access to novel antivirals is still poor in the country. The
duration from onset of symptoms to hospital admission,
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The COVID-19 disease spectrum ranges from asymptomatic, mild, moderate, severe to critical disease.4 About
5% of patients have critical disease, which is defined as
respiratory failure, shock or multiorgan dysfunction,
usually exacerbated by immune hyperactivation such
as the cytokine storm.5 The most common laboratory
findings include lymphopenia, elevated aminotransferases, elevated lactate dehydrogenase, elevated C reactive
protein (CRP) and elevated D-dimer levels.6 Common
chest radiological findings include ground glass opacities
in 83%, mixed ground glass opacities and consolidation
in 58%, pleural thickening in 50% and interlobular septal
thickening in 48%.7
The overall COVID-19 case fatality rate approximates
2.3%.5 Most fatalities are patients with advanced age
or underlying comorbidities. Case fatality also varies by
region depending on population characteristics, for
example, Italy which has an older population reported
a case fatality rate of 7.2% as compared with Korea
where the median age is 40 years and the case fatality
rate was 0.7%.8 9 In an analysis of 3 00 000 patients with
confirmed COVID-19 in the USA, mortality was 12 times
higher among patients with comorbidities.10 Comorbidities shown to be risk factors for severe illness include
cardiovascular disease, smoking, diabetes mellitus, hypertension, chronic lung disease, chronic kidney disease
and obesity.5 Some laboratory findings have been also
associated with poor outcomes. These include lymphopenia, thrombocytopenia, deranged liver function tests,
elevated lactate dehydrogenase and raised inflammatory
markers.11
Whereas detailed reports of clinical features and
outcomes of patients hospitalised with COVID-
19 are
increasing from various parts of the world, data from
Africa are scarce. In this paper, we report the epidemiological and clinical features of patients admitted with
COVID-
19 to Kenyan Hospitals and describe the risk
factors for mortality.

Open access

Data analysis
Categorical variables were presented as counts and
percentages, and continuous variables as means with SD
for normally distributed data or median with IQRs for
data that were not normally distributed. Independent
group t tests were used to compare means of continuous
variables for normally distributed data, and the non-
parametric Mann-Whitney U test for data that were not
normally distributed. Comparison between proportions
of categorical variables was done using the χ2 tests. Data
from laboratory tests were categorised as normal (within
the reference range) or abnormal (outside the reference
range).
For survival analysis, the primary outcome of this
study was COVID-
19-
related death, defined as death
among patients admitted into the hospital with reverse
transcriptase-PCR-confirmed SARS-CoV-2 infection and
complications associated with COVID-
19. Cox proportional hazards regressions were used to calculate HRs
associated with demographics, underlying comorbidities,
symptoms, clinical and laboratory characteristics and the
CIs set at 95%. All the statistical analyses were carried out
using the R statistical software.12

Laboratory findings of the patients
To determine the laboratory findings associated with
survival of patients admitted with COVID-
19, various
blood tests were conducted. The tests included haematology for 448 (57%) of the patients, creatinine (n=433,
55%), D-dimer (n=94, 12%), liver function tests (n=421,
53%), CRP (n=184, 23%) and procalcitonin (n=14, 2%).
A majority of patients analysed had neutropenia, lymphopenia, elevated aspartate aminotransferase, elevated
lactate dehydrogenase and elevated CRP. The results
showed differences in many of these parameters when
compared between the survivors and the non-survivors
(table 2).
Radiological features
Severely ill patients got chest imaging (n=101). The
most common findings included presence of ground
glass opacities in 73 (72%), local patchy shadowing in 59
(58%), diffuse patchy shadowing in 61 (60%) and interstitial abnormalities in 29 (29%).
Determinants of time-to-death for patients with COVID-19
admitted in health facilities
To determine the factors associated with death for hospitalised patients with COVID-
19, we carried out Cox
proportional hazard regression analysis. This was carried
out in two stages: univariable analysis of all putative
factors, followed by multivariable analysis to identify the
significant factors associated with death. Table 3 shows the
results of the univariable analysis for all putative factors in
the study data set for COVID-19 mortality. Factors with a
p value of <0.2 were offered to the multivariable analysis
followed by model reduction.
Figure 1 shows the association between the patient-level
factors and risk of COVID-19 mortality among the hospitalised patients. Risk of death increased with age with
patients over 60 years of age having more than one and
half increased risk of death compared with those below 60
years (HR 1.57 (1.13 to 2.19)). Men had a higher risk of
COVID-19 mortality compared with women, while those
with at least one underlying comorbidity had an increase
in risk of death compared with those without. Presence
of clinical symptoms was associated with increased risk of
COVID-19 mortality.
Several laboratory test results were associated with
higher risk of mortality (figure 2). Increased white cell
counts, both neutrophilia and neutropenia as well
as lymphopenia, low haemoglobin and elevated liver
enzymes were associated with increased risk of death
from COVID-19.

RESULTS
Baseline characteristics of the study patients
A total of 787 patients from six health facilities were
recruited into the study. The median age was 43 years,
with 42% of the patients being below 40 years. Majority
of the patients (64%) were men. Nearly two-thirds (67%)
of the patients had visited the health facility either after
developing symptoms or due to other concerns while
the rest had been admitted following the initial government regulations of isolating all laboratory-confirmed
positive cases in health facilities. Of the admitted
patients, 43% had underlying conditions, with the most
common being cardiovascular diseases (17%), diabetes
(15%), HIV (7%), cancer (4%), chronic renal disease
(3%) and chronic obstructive pulmonary disease (3%)
(table 1).
More than half (58%) of the patients were reported
to have clinical symptoms during admission, with cough
(43%), loss of taste or smell (35%), fever (16%), headaches (13%) and muscle pains (12%) being the most
frequent. Seventy-nine (11%) of patients required ICU
admission and 59 (7%) were mechanically ventilated.
A total of 107 (13.5%) patients died. From the onset of
symptoms, the average duration of hospital admission
and ICU admission and death were 7 and 6 days, respectively, and the average time to death was 16 days. Table 1
provides a summary of the baseline characteristics of the
patients included in the study.

DISCUSSION
This prospective, multicentre study provides a summary
of the epidemiological and clinical features of people
CoV-
2 infection and COVID-
19 of varying
with SARS-
severity and explores predictors of mortality.
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to requiring ventilation, to ICU admission and to death
was recorded.
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Parameter

All patients (n=787)

Survivors (n=680)

Non-survivors (107)

P value

Age in years median (SD)
 0–20

43 (0–109)
70 (9%)

41 (0–109)
66 (10%)

55 (0–85)
4 (4%)

<0.001
0.067

 21–40

278 (35%)

263 (39%)

15 (14%)

<0.001

 41–60

315 (40%)

272 (40%)

43 (40%)

1

 60

124 (16%)

79 (12%)

45 (42%)

<0.001

Sex

0.205

 Male

505 (64%)

430 (63%)

75 (70%)

 Female

282 (36%)

250 (37%)

32 (30%)

Healthcare workers

53 (7%)

52 (8%)

1 (1%)

0.006

Patient presented at health facility

524 (67%)

418 (61%)

106 (99%)

<0.001

Underlying comorbidity

340 (43%)

267 (39%)

73 (68%)

<0.001

 Cardiovascular disease

130 (17%)

98 (14%)

32 (30%

<0.001

 Diabetes

116 (15%)

87 (13%)

29 (27%)

<0.001

 HIV

53 (7%)

42 (6%)

11 (10%)

0.172

 Cancer

30 (4%)

22 (3%)

8 (7%)

0.063

 Chronic renal disease

24 (3%)

14 (2%)

10 (9%)

<0.001

 Chronic obstructive pulmonary disease

21 (3%)

13 (2%)

8 (7%)

0.003

455 (58%)

376 (55%)

79 (74%)

<0.001

Symptoms at admission
Present during admission
 Cough

337 (43%)

284 (42%)

53 (50%)

0.160

 Loss of taste or smell

279 (35%)

208 (31%)

71 (66%)

<0.001

 Fever

126 (16%)

108 (16%)

18 (17%)

0.917

 Headache

99 (13%)

94 (14%)

5 (5%)

0.013

 Muscle pains

98 (12%)

80 (9%)

18 (17%)

0.188

 Fatigue

70 (9%)

66 (10%)

4 (4%)

0.069

 Body weakness

35 (4%)

29 (4%)

6 (6%)

0.708

 Chest Pains

26 (3%)

23 (3%)

3 (3%)

0.984

7 (0–53)

7 (0–53)

7 (0–38)

0.846

 ii) ICU admission

6 (0–38)

7 (0–25)

 iii) Death

16 (1–65)

Duration of onset of symptoms to:
 i) Hospital admission

5 (0–38)

0.282

16 (1–65)

<0.001

46 (43%)
46 (43%)

<0.001
<0.001

Hospital course
 ICU admission
 Ventilation

90 (11%)
59 (7%)

44 (6%)
13 (2%)

ICU, intensive care unit.

Among COVID-
19-
positive patients admitted to six
COVID-19 hospitals in Kenya between March and August
2020, the median age was 43 years, with 42% below the
age of 40 and majority were men (64%). About 43%
were found to have underlying chronic conditions,
most commonly cardiovascular disease (17%), diabetes
mellitus (15%), HIV (7%), malignancies (4%), chronic
kidney disease (3%) and chronic airway disease (3%).
The incidence of ICU admission was 90 (11%) with
59 (7%) patients receiving mechanical ventilation. This
incidence of severe illness requiring ICU admission is

lower than that observed in other cohorts largely from
developing countries. Cummings et al report on a New
York cohort, in which the incidence of ICU admission was
22%.13
There are several factors that may account for this
lower disease severity. The initial Kenya national containment strategy included admission of all persons testing
COVID-19 positive even in the absence of symptoms, this
was at a time when over 80% of the patients were asymptomatic.14 Our patient population was also younger than
that reported elsewhere, with a median age of the general
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Table 1 Demographics and baseline characteristics of the patients admitted in Kenyan health facilities with COVID-19
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Parameter
9

Leucocyte count (×10 L; normal range 4–10)
 Increased

All patients

Survivors

Non-survivors

P value

n=448
99 (22%)

n=352
55 (16%)

n=96
44 (46%)

<0.001

n=354

n=94

223 (63%)

66 (70%)

<0.001
0.468

Segmented neutrophils (normal range 45%–75%)
 Decreased

289 (65%)

 Increased

41 (11%)

Lymphocyte (normal range 25%–40%)

23 (6%)

18 (19%)

n=355

n=93

 Decreased

309 (69%)

227 (64%)

82 (88%)

<0.001

 Increased

60 (13%)

58 (16%)

2 (2%)

<0.001

Haemoglobin (g/dL normal range: male 14–17, female 12–16)

n=448

n=349

n=99

 Decreased

128 (29%)

76 (22%)

52 (53%)

Aminotransferase, alanine (U/L normal range:<35)

n=421

n=316

n=105

 Increased

201 (48%)

132 (42%)

69 (66%)

Aminotransferase, aspartate (U/L normal range:<35)

n=421

n=316

n=105

 Increased

214 (51%)

131 (41%)

83 (79%)

<0.001
<0.001
<0.001

Lactose dehydrogenase (U/L normal range: 60–100)

n=104

n=66

n=38

 Increased

101 (97%)

64 (97%)

37 (97%)

Potassium (mmol/L normal range: 3.5–5)

n=433

n=328

n=105

 Decreased

35 (8%)

28 (9%)

7 (7%)

0.030

 Increased

61 (15%)

38 (12%)

23 (22%)

0.178

C reactive protein (mg/L normal range:<5)
 Increased

n=197
155 (79%)

n=137
96 (70%)

n=60
59 (98%)

<0.001

1

population of 20 years compared with 45 in Italy and 44.9
in Spain, 38.2 in USA and 33 in Brazil, all countries that
have seen significantly higher morbidity and mortality. In
the New York cohort, they reported a mean age of 62 years
and a high prevalence of hypertension (63%) in patients
admitted to the critical care units.13 The prevalence of
underlying chronic conditions was lower in our cohort
than that reported elsewhere. De Souza and others in
an analysis of the epidemic in Brazil report prevalence
of 66.5% of cardiovascular disease and 54.5% diabetes
in patients with COVID-19.15 Older age and presence of
underlying comorbidities have both been associated with
increased risk of severe outcomes in COVID-19.16 17
Fifty-eight per cent of our patients were symptomatic at
the time of admission with the most common symptoms
being cough (58%), loss of taste and smell (35%) and
fever (16%). Earlier reports on the epidemic reported
fever as the most common symptom followed by cough.
In a systematic review and meta-analysis, Hu found the
prevalence of fever to be 85.6%, cough at 65.7%, other
common symptoms were fatigue and dyspnoea.18 Loss of
smell and taste was fairly prevalent in our population as
has been reported elsewhere.19
Non-survivors were more likely to be older, have an
underlying comorbidity with cardiovascular disease,
diabetes mellitus, renal insufficiency and chronic
obstructive airway disease more likely to be present
in non-survivors. This is in keeping with reports from

other cohorts.20 Many chronic diseases may lead to a
state of heightened inflammation and impaired immune
responses with an overall lowering of immunity.
On Cox proportional hazard regression analysis, we
found significantly increased risk of death with older age
(>60), male gender and in patients with comorbidities.
Men with COVID-19 have been shown to be at higher
risk for worse outcomes and mortality irrespective of
age.21 Malhotra et al in a retrospective cohort study in
Delhi, looking at 10 314 patients, found that mortality was
higher in male patients and with increasing age . Elderly
women (>75 years) were noted to have the highest odd
of mortality, which was thought to reflect on the poorer
healthcare access by this population.22 Possible explanations for the higher mortality in men include the higher
prevalence of high-risk behaviour including smoking and
attendant lung injury, higher prevalence of underlying
comorbidities and other yet to be fully defined biologic
differences.
We found that the presence of a comorbidity was
associated with increased mortality, HR 2.34 (CI 1.69 to
3.25). Comorbidities have been associated with higher
risk of severe outcomes in many populations. Data from
China showed that the HR of severe outcomes including
admission to ICU, invasive ventilation and death was 1.79
for patients with at least one comorbidity and 2.59 for
patients with two or more comorbidities.17
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Characteristic

HR

95% CI

P value

Age group (n=787) (Reference:<20)
 21–40

1.58

0.62 to 4.06

0.3

 41–60

3.66

1.49 to 9.03

0.005

 >60

5.61

2.24 to 14.0

<0.001

1.62

1.17 to 2.24

0.004

2.62

1.92 to 3.58

<0.001

 HIV

1.49

0.83 to 2.68

0.2

 Chronic renal disease

2.77

1.80 to 4.25

<0.001

 Asthma

1.06

0.26 to 4.26

>0.9

 Tuberculosis

1.38

0.34 to 5.58

0.6

 Diabetes (n=740)

2.02

1.44 to 2.85

<0.001

12.3

9.06 to 16.6

<0.001

106

14.7 to 758

<0.001

 Yes

1.92

1.38 to 2.67

<0.001

Symptoms existing (n=787) (reference: no)

1.13

1.04 to 1.22

0.003

 Headache

0.33

0.18 to 0.62

<0.001

 Fatigue

0.53

0.31 to 0.90

0.020

 Myalgia or arthralgia

0.24

0.03 to 1.71

0.2

 Shortness of breath

1.97

1.34 to 2.89

<0.001

 Fever

1.92

1.39 to 2.65

<0.001

 Cough

1.25

0.93 to 1.67

0.14

 Sore throat

1.86

0.92 to 3.79

0.086

 Weakness

1.80

1.02 to 3.16

0.042

 Chest pains (n=740)

0.62

0.25 to 1.50

0.3

 Loss of taste or smell

3.43

2.52 to 4.68

<0.001

 Decreased

0.57

0.26 to 1.24

0.2

 Increased

3.14

2.27 to 4.34

<0.001

 Decreased

3.34

1.88 to 5.95

<0.001

 Increased

6.13

3.22 to 11.7

<0.001

 Decreased

4.17

1.95 to 8.90

<0.001

 Increased

0.30

0.06 to 1.45

0.13

 Decreased

2.81

2.01 to 3.92

<0.001

 Increased

0.88

0.40 to 1.94

0.8

Alanine aminotransferase (n=500) (reference: normal)
 Increased

2.13

1.54 to 2.95

<0.001

Gender (n=787) (reference: female)
 Male
Chronic conditions (n=787) (reference: no)
 Yes
Chronic conditions existing (n=787) (reference: no)

Ventilation (n=787) (reference: no)
 Yes
Reason hospitalisation (n=787) (reference: other reason)
 Visited hospital
Clinical symptoms (n=787) (reference: no)

White blood cells (n=558) (reference: normal)

Neutrophils (n=559) (reference: normal)

Lymphocytes (n=558) (reference: normal)

Haemoglobin (n=554) (reference: normal)

Continued
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Characteristic

HR

95% CI

P value

3.24

2.25 to 4.68

<0.001

 Decreased

1.15

0.65 to 2.05

0.6

 Increased

1.72

1.20 to 2.46

0.003

C reactive protein (n=263) (reference: normal)
 Increased

25.9

3.61 to 186

0.001

Aspartate aminotransferase (n=502) (reference: normal)
 Increased
Potassium (n=539) (reference: normal)

As countries think of strategies to reduce disease transmission and reduce risk of severe disease and mortality, it
is important that these risk factors of older age and presence of comorbidity are taken into account and strategies
that identify and shield those at highest risk as defined
here are adopted.
We found various laboratory parameters to be associated with increased risk of death, these included leucocytosis, lymphopaenia, transaminitis and elevated CRP.
Lymphopaenia has been shown to occur frequently in
patients with COVID-19 and to predict severe disease.23
Lymphopaenia may result either from suppression of the
bone marrow, direct infection and destruction or a cytotoxic-
mediated killing of lymphocytes. A functional exhaustion of
antiviral lymphocytes has also been reported.24
We found elevated alanine and aspartate aminotransferase in 48% and 51% of patients, respectively. Elevations
in liver enzymes are common and have been reported to
range from 16% to 53% in various studies.25 26 Boregowda

et al, in a meta-analysis of studies comparing liver chemistries in mild and severe disease, showed that elevated
liver enzymes were associated with severe disease and also
predicted mortality.26 This finding is further strengthened by our study where the presence of elevated aspartate aminotransferase was associated with a HR of death
of 2.5 (CI 1.69 to 3.7)
Some of the limitations of our study included the fact
that in the initial phase of COVID-19, patients did not
routinely get pulse oximetry, hence determination of
severity of disease at presentation was not always done.
Several other laboratory parameters that have been shown
to predict severity of disease such as D-dimer, Ferritin,
IL-6 were not routinely measured.

Figure 1 Figure showing the hazard ratios of the statistically
significant factors in the multivariable model that are
associated with death outcomes among COVID-19 patients
admitted in the health facilities.

Figure 2 Figure showing the hazard ratios of the laboratory
parameters from the multivariate model. An increase in
aspartate, decrease in haemoglobin and an increase in the
white blood cells increased the hazard ratio by more than 2.
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CONCLUSION
In conclusion, this study demonstrates that patients with
COVID-19 in Kenya were fairly young with a low rate of
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severe disease. Age above 60, male gender, presence of
comorbidities, leucocytosis, lymphopaenia and elevated
transaminases predicted mortality.

